Oncurious going to the 'next level' with I-O assets

1 September 2017

In an all Belgian deal, biotech company Oncurious has reached principle agreement with the life sciences research institute VIB to acquire exclusive licenses to a portfolio of five unique next generation immuno-oncology (I-O) assets.

The company is a venture between biopharma firm ThromboGenics (EBR: THR) and VIB, and the latter will increase its stake in Oncurious as part of the agreement.

VIB will receive a royalty on future sales of any of the assets. ThromboGenics, which remains the majority shareholder, is investing an additional 2.1 million euros ($2.5 million) in Oncurious.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK